{
    "id": 10711,
    "fullName": "PDGFB fusion",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDGFB fusion indicates a fusion of the PDGFB gene, but the fusion partner is unknown.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5155,
        "geneSymbol": "PDGFB",
        "terms": [
            "PDGFB",
            "c-sis",
            "IBGC5",
            "PDGF-2",
            "PDGF2",
            "SIS",
            "SSV"
        ]
    },
    "variant": "fusion",
    "createDate": "08/20/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2930,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Kisqali (ribociclib) inhibited proliferation of a Gleevec (imatinib)-resistant dermatofibroscarcoma cell line harboring deletion of both CDKN2A and CDKN2B and a PDGFB rearrangement (PMID: 25852058).",
            "molecularProfile": {
                "id": 10737,
                "profileName": "PDGFB fusion CDKN2A del CDKN2B del"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3507,
                "name": "dermatofibrosarcoma protuberans",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3535,
                    "pubMedId": 25852058,
                    "title": "CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25852058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10736,
            "profileName": "PDGFB fusion",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10737,
            "profileName": "PDGFB fusion CDKN2A del CDKN2B del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}